NIMble innovation—a networked model for public antibiotic trials

Summary: Antibiotic research and development is at an inflection point. Faced with ongoing problems with commercial innovation, we argue for a networked public approach to support and coordinate existing research and development initiatives by sustainably moving promising compounds through clinical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rebecca E Glover, PhD, Andrew C Singer, PhD, Adam P Roberts, PhD, Claas Kirchhelle, PhD
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Medicine (General) R5-920 Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/aacf5652e8a54576992a5c2ec4b50189
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aacf5652e8a54576992a5c2ec4b50189
record_format	dspace
spelling	oai:doaj.org-article:aacf5652e8a54576992a5c2ec4b501892021-11-04T04:41:06ZNIMble innovation—a networked model for public antibiotic trials2666-524710.1016/S2666-5247(21)00182-8https://doaj.org/article/aacf5652e8a54576992a5c2ec4b501892021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666524721001828https://doaj.org/toc/2666-5247Summary: Antibiotic research and development is at an inflection point. Faced with ongoing problems with commercial innovation, we argue for a networked public approach to support and coordinate existing research and development initiatives by sustainably moving promising compounds through clinical trials. We propose a global public infrastructure of institutes tasked with (1) conducting all trial stages up to market authorisation, including small-scale compound production; (2) negotiating licensing agreements for global production and distribution by industry partners; and (3) using public purchasing agreements or subscription models to ensure commercially viable drug production at equitable prices. We invite stakeholders to consider our Networked Institute Model's benefits for unblocking the public and private antibiotic pipeline.Rebecca E Glover, PhDAndrew C Singer, PhDAdam P Roberts, PhDClaas Kirchhelle, PhDElsevierarticleMedicine (General)R5-920MicrobiologyQR1-502ENThe Lancet Microbe, Vol 2, Iss 11, Pp e637-e644 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920 Microbiology QR1-502
spellingShingle	Medicine (General) R5-920 Microbiology QR1-502 Rebecca E Glover, PhD Andrew C Singer, PhD Adam P Roberts, PhD Claas Kirchhelle, PhD NIMble innovation—a networked model for public antibiotic trials
description	Summary: Antibiotic research and development is at an inflection point. Faced with ongoing problems with commercial innovation, we argue for a networked public approach to support and coordinate existing research and development initiatives by sustainably moving promising compounds through clinical trials. We propose a global public infrastructure of institutes tasked with (1) conducting all trial stages up to market authorisation, including small-scale compound production; (2) negotiating licensing agreements for global production and distribution by industry partners; and (3) using public purchasing agreements or subscription models to ensure commercially viable drug production at equitable prices. We invite stakeholders to consider our Networked Institute Model's benefits for unblocking the public and private antibiotic pipeline.
format	article
author	Rebecca E Glover, PhD Andrew C Singer, PhD Adam P Roberts, PhD Claas Kirchhelle, PhD
author_facet	Rebecca E Glover, PhD Andrew C Singer, PhD Adam P Roberts, PhD Claas Kirchhelle, PhD
author_sort	Rebecca E Glover, PhD
title	NIMble innovation—a networked model for public antibiotic trials
title_short	NIMble innovation—a networked model for public antibiotic trials
title_full	NIMble innovation—a networked model for public antibiotic trials
title_fullStr	NIMble innovation—a networked model for public antibiotic trials
title_full_unstemmed	NIMble innovation—a networked model for public antibiotic trials
title_sort	nimble innovation—a networked model for public antibiotic trials
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/aacf5652e8a54576992a5c2ec4b50189
work_keys_str_mv	AT rebeccaegloverphd nimbleinnovationanetworkedmodelforpublicantibiotictrials AT andrewcsingerphd nimbleinnovationanetworkedmodelforpublicantibiotictrials AT adamprobertsphd nimbleinnovationanetworkedmodelforpublicantibiotictrials AT claaskirchhellephd nimbleinnovationanetworkedmodelforpublicantibiotictrials
_version_	1718445232527245312

NIMble innovation—a networked model for public antibiotic trials

Ejemplares similares